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INTRODUCTION
The CITRIS-ALI trial was a randomized clinical trial assessing the effect of vitamin C on organ
failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe
acute respiratory failure (1). Patients with sepsis and acute respiratory distress syndrome were
administered 50 mg/kg vitamin C intravenously for four days. The trial report states that, “The
Kaplan-Meier survival curves for the 2 groups were significantly different by the Wilcoxon test
(χ2
[1df ]
= 6.5; P = 0.01)” (1). However, this finding was not mentioned in the abstract and it was
downplayed in the discussion section.
Previously, we conducted a meta-analysis of 12 controlled trials assessing the effect of vitamin
C on intensive care unit (ICU) length of stay. The meta-analysis included 1,766 patients and found
that vitamin C shortened ICU stay on average by 8% (95% CI: 4-11%) (2). One of the included
trials found that vitamin C reduced mortality in sepsis patients by 78% (P = 0.01) (3). Both our
meta-analysis and this trial are relevant when considering the effect of vitamin C on ICU patients,
but neither was cited in the CITRIS-ALI trial report (1).
The CITRIS-ALI trial report suggested that the effect of vitamin C on mortality might be
explained by multiple comparisons (1). The purpose of this reanalysis is to argue that the multiple
comparisons issue is an unlikely explanation for the published survival findings.
REANALYSIS OF THE CITRIS TRIAL
In the CITRIS-ALI trial registration, mortality was listed as one of 18 secondary outcomes (4).
Most of them are biomarkers with little clinical importance. Only four secondary outcomes are
unambiguously clinically relevant: ventilator-free days, ICU-free days, hospital-free days, and
mortality. The effect of vitamin C was statistically significant for three of them: ICU-free days,
hospital-free days, and mortality (1). Furthermore, none of the secondary or primary outcomes
matches mortality in terms of clinical importance.
In the discussion section (1), Fowler et al. write that “Among the 46 secondary outcomes that
were examined in this trial, 43 showed no significant differences between the vitamin C group and the
placebo group, although vitamin C compared with placebo was associated with a significant reduction
in 28-day all-cause mortality, and with significantly increased ICU-free days to day 28 and hospital-
free days to day 60. However, these findings were based on analyses that did not account for multiple
comparisons and therefore must be considered exploratory.” This comment misleads the readers.
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First, the trial registration listed just 18 secondary outcomes
(4). Although many of them were measured at several time
points, this should not equate to 46 independent secondary
outcomes. If vitamin C has no effect on a biomarker, it is
likely that the lack of effect is uniform over time. Counting the
measurements at several time points as if they were independent
makes the multiple comparison issue appear much greater than
it is.
Second, a researcher interested in the effects of vitamin C
on mortality can legitimately deny interest in the secondary
outcomes that are just biomarkers such as the levels of
platelets, bilirubin, procalcitonin, tissue factor pathway inhibitor,
receptor for advanced glycation endpoints, and so on (4).
The use of biomarkers has been popular since measuring
biomarkers/surrogates is much quicker and much less expensive
than measuring clinically relevant outcomes. However, the
wide-spread use of surrogates has been severely criticized.
There are numerous examples that demonstrate that the
effects on surrogate endpoints can diverge from the effects
on clinically relevant outcomes (5–8). However, four of the
measured outcomes in the CITRIS-ALI trial were clinically
relevant. When there is a significant difference between the
treatment groups in three out of four of the clinically relevant
outcomes, and a significant effect for the most important
outcome, mortality (1), the multiple comparisons issue is not a
valid explanation for the findings. The measurement of many
biomarkers should not be used to dismiss the findings on the
clinically relevant outcomes. Although multiple comparisons are
a concern when researchers calculate numerous associations
without justified research questions, the issue has often been
greatly exaggerated (9–11).
Third, prior learning is relevant for determining research
questions and interpreting findings. Given that in earlier studies
vitamin C was found to shorten ICU and hospital stay (2, 12),
and decrease mortality (3), research on these clinically relevant
outcomes is not a fishing expedition without biological rationale,
but testing well-justified hypotheses. This previous research on
vitamin C and the three clinically relevant outcomes was not
considered by Fowler et al. (1).
In addition to exaggerating the multiple comparisons
problem, the analysis of mortality findings was not optimal in
the CITRIS-ALI trial. Vitamin C was administered for four days,
but mortality was analyzed over 28 days. Thus, if vitamin C had
an effect only around the time of administration, extension of
the mortality analysis by 24 days in the absence of vitamin C
may camouflage any potential benefits. Inspection of the survival
curves (1) indicates that the vitamin C and placebo groups
differed in the early follow-up, but not in the late follow-up. These
differences can be tested statistically.
When separate vitamin C effects in the early and late follow-up
periods are accounted for, the improvement in the Cox regression
model can be calculated by the likelihood ratio test.Table 1 shows
that adding a separate early period vitamin C effect for four days
leads to the greatest improvement in the Cox regression model.
The best-fitting model in Table 1 indicates that vitamin C
decreased mortality in the period up to day 4 with RR = 0.19
(95% CI 0.06-0.55), but had no effect from day 5 onwards with
TABLE 1 | Improvement in the Cox regression model by allowing different vitamin
C effects for two consecutive time periods.





0-1 and 2-28 4.54 0.033
0-2 and 3-28 4.82 0.028
0-3 and 4-28 6.52 0.011
0-4 and 5-28 7.65 0.006
0-5 and 6-28 7.22 0.007
0-6 and 7-28 3.49 0.061
0-7 and 8-28 1.41 0.236
*The improvement in the Cox regression model over the reference model was tested by
the likelihood ratio test. The reference model estimates that vitamin C decreases mortality
uniformly by RR = 0.57 (95% CI: 0.34-0.95; P = 0.028). Compared with the model with
no vitamin C effect, the best-fitting two-period model (0–4 days and 5–28 days) improves
the Cox regression with χ2(2df ) = 12.5 (P = 0.002). See the Supplementary File for
the extraction of mortality data from Figure 3 of the CITRIS-ALI trial report (1) and the
calculations for this table.
RR = 0.95 (95% CI 0.50-1.79). Compared to the model with no
vitamin C effect over the 28-day period, this two-period model
improves the Cox regression with χ2
(2df)
= 12.5 (P = 0.002).
This strong evidence of within-follow-up heterogeneity in the
vitamin C effect further challenges the suggestion that the effect
of vitamin C on mortality may have been an artifact explained
by multiple comparisons (1). If the overall difference between the
vitamin C and placebo groups is assumed to be caused purely by
random variation, we would not expect to observe such strong
evidence of systematic differences between the early and late
follow-up periods.
Furthermore, given that vitamin C was administered for only
four days, it is reasonable to examine the effect of vitamin C on
mortality over the same period. By the end of day 4, the mortality
rate was 22.9% (19/83) in the placebo group and 4.8% (4/84) in
the vitamin C group, with P = 0.0007. This difference of 18.1
percentage points corresponds to the number needed to treat
equal to 5.5 (95% CI: 3.5–12.5).
Fowler et al. calculated P = 0.01 for the difference between
the survival curves for the vitamin C and placebo groups (1).
However, as shown above, the evidence for vitamin C is much
stronger if the analysis is restricted to the four days during which
vitamin C was administered, or if two distinct periods for the
effect of vitamin C are accounted for.
There is evidence that the effects of vitamin C may be greatest
for ICU patients who are the most ill (2, 13). It is likely that
patients in the CITRIS-ALI trial who were alive a week after the
start of treatment were less ill at baseline compared with those
who died within four days. Thus, the evidence for greater benefit
for the most ill patients also motivates a separate analysis over the
early part of the follow-up.
There are numerous potential biochemical explanations for
the effects of vitamin C on severely ill patients (2, 14–16).
It participates in the synthesis of norepinephrine, carnitine,
nitric oxide, and several neuropeptides. It also participates in
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the demethylation of DNA and histones and thereby influences
the epigenome; vitamin C may demethylate over 1,000 genes
in embryonic stem cells. Vitamin C also hydroxylates specific
proline residues in hypoxia-inducible factor-I, which is a
transcription factor involved in oxygen sensing, and thereby may
regulate several hundred genes. Finally, as a major antioxidant
vitamin C can have a wide range of nonspecific effects.
CONCLUSIONS
The CITRIS-ALI trial findings indicate that the effect of vitamin
C on mortality is not equal to placebo. This is an important
finding which should not be dismissed solely because of the
multiple comparisons issue. It is noteworthy that the 81%
decrease in mortality during vitamin C administration in the
CITRIS-ALI trial is similar to the previously reported 78%
decrease in mortality (3). Nevertheless, it is unlikely that this
estimate can be widely generalized because there is evidence
indicating that the effect of vitamin C on ICU patients depends
substantially on the illness-severity of patients (13). Further
research is required to investigate this relationship.
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